国产药物洗脱支架对急性ST段抬高型心肌梗死预后的影响

目的 探讨国产药物支架（DES）对急性ST段抬高型心肌梗死（STEMI）预后的影响.方法 对2004-03～2009-04共216例确诊为STEMI的患者分为两组,药物支架（DES）组（n=117）和裸支架（BMS）组（n=99）,术后长期随访,观察术后12个月随访终点时支架内再狭窄发生率（ISR）及主要心血管不良事件（包括死亡、急性心肌梗死、靶血管再成形等）发生率.结果 216例患者经皮冠状动脉介入（PCI）治疗均成功.介入治疗3～12个月后随访结果 显示,DES组再狭窄率明显低于BMS组（P〈0.05）,两组心血管不良事件发生率差异无统计学意义（P〉0.05）.结论 DES在STEMI患者中有较好的安全性及临床疗效,再狭窄率明显低于BMS（P〈0.05）.

Safety and effectiveness of firebird drug eluting stent in acute ST-segment elevation myocardial infarction

Objective To evaluate the safety and effectiveness of firebird drag eluting stentt （DES） in acute ST-segment elevation myocardial infarction. Methods 216 patients with acute ST-segment elevation myocardial infarction from March 2004 to April 2009 were divided into two groups： DES group（n = 117） and BMS group（n =99）. The occurrence rate of in-stentt restenosis （ISR） and major adverse cardiovascular event （sudden death, reinfarction, revascularization） were analyzed after 12 months of implantation. Results Both groups showed a success rate of 100% in stenting. DES group was much better than BMS group in aspect of ISR（P 〈0. 05）. There were no statistic difference in aspect of major adverse cardiovascular event （P 〉 0. 05 ） after 3 to 12 months of implantation. Conclusion DES implanted in patients with acute ST-segment elevation myocardial infarction is safety and effectiveness, DES is much better than BMS in aspect of ISR（P 〈0. 05）.